Janux Therapeutics Inc JANX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 10:10 AM EDT
48.90quote price arrow up+0.99 (+2.07%)
Volume
146,376
52 week range
5.65 - 65.60
Loading...
  • Open49.22
  • Day High49.87
  • Day Low48.49
  • Prev Close47.91
  • 52 Week High65.60
  • 52 Week High Date05/03/24
  • 52 Week Low5.65
  • 52 Week Low Date11/10/23

Key Stats

  • Market Cap2.535B
  • Shares Out51.85M
  • 10 Day Average Volume1.01M
  • Dividend-
  • Dividend Yield-
  • Beta3.88
  • YTD % Change355.64

KEY STATS

  • Open49.22
  • Day High49.87
  • Day Low48.49
  • Prev Close47.91
  • 52 Week High65.60
  • 52 Week High Date05/03/24
  • 52 Week Low5.65
  • 52 Week Low Date11/10/23
  • Market Cap2.535B
  • Shares Out51.85M
  • 10 Day Average Volume1.01M
  • Dividend-
  • Dividend Yield-
  • Beta3.88
  • YTD % Change355.64

RATIOS/PROFITABILITY

  • EPS (TTM)-1.22
  • P/E (TTM)-39.94
  • Fwd P/E (NTM)-36.44
  • EBITDA (TTM)-70.825M
  • ROE (TTM)-11.50%
  • Revenue (TTM)7.287M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-762.92%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/06/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Janux Therapeutics Inc

 

Profile

MORE
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory...
Jay Lichter Ph.D.
Chairman of the Board
David Campbell Ph.D.
President, Chief Executive Officer, Founder, Director
Tighe Reardon
Acting Chief Financial Officer
Charles Winter
Chief Technology Officer
Address
10955 Vista Sorrento Parkway, Suite 200
San Diego, CA
92130
United States

Top Peers

SYMBOLLASTCHG%CHG
RNA
Avidity Biosciences Inc
28.59-0.32-1.12%
APGE
Apogee Therapeutics Inc
53.35-0.65-1.20%
MLTX
MoonLake Immunotherapeutics
41.60+0.83+2.04%
CLDX
Celldex Therapeutics Inc
40.72+1.25+3.17%
MRUS
Merus NV
45.69+0.92+2.05%